眾合科技(000925.SZ):浙江海納取得同意在新三板掛牌的函
格隆匯2月21日丨眾合科技(000925.SZ)公佈,2023年2月17日,浙江海納收到全國股轉公司出具的《關於同意浙江海納半導體股份有限公司股票在全國中小企業股份轉讓系統掛牌的函》(股轉函〔2023〕377號),全國股轉公司同意浙江海納股票在全國中小企業股份轉讓系統掛牌公開轉讓,交易方式為集中競價交易。
浙江海納在全國中小企業股份轉讓系統掛牌有利於增強市場競爭力,拓展融資渠道,提升資產運營效率和價值,符合眾合科技的長期發展戰略。且浙江海納在全國中小企業股份轉讓系統掛牌後,仍為眾合科技合併報表範圍內的子公司,不會對眾合科技持續經營運作構成實質性影響,不影響眾合科技的上市地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.